Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Ventus Therapeutics
About
Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.
- 51 - 100
Details
- Last Funding Type
- Corporate Round
- Last Funding Money Raised
- $70M
- Industries
- Biotechnology,Health Care,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2019
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Ventus' structural immunology platform offers unprecedented insight into mechanisms and molecular structures, combining core capabilities for precisely targeting the innate immune system: proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. Ventus has built an emerging pipeline of multiple drug programs addressing key targets in the innate immune system.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 29, 2022 | Corporate Round | $70M | 1 |
Novo Nordisk
|
— | Detail |
| Feb 9, 2022 | Series C | $140M | 1 | — | — | Detail |
| Apr 8, 2021 | Series B | $100M | 1 | — | — | Detail |
| May 6, 2020 | Series A | $60M | 1 |
Versant Ventures
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Novo Nordisk
|
Yes | Corporate Round |
|
Versant Ventures
|
— | Series C |
